XmAb541
Phase 1Biologic
XmAb541 is one of 49 biologic programs targeting Ovarian Cancer. It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
207 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Hycamtin
MMeitheal
Phase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Adriamycin
PfizerPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Neulasta
AmgenPhase 3
Taxotere
AAvyxa
Phase 3
Elahere
IImmunogenics, LLC
Phase 3
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XmAb541. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- XXencor, Inc.